Atara Biotherapeutics, Inc.
ATRA· Nasdaq
Released Mar 27, 2024, after the close
10-K filed Mar 28, 2024, 88 days after period end · 0000950170-24-037644
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $4.25M | $221.00K | — | — |
| Net Income | -$60.45M |
Atara Biotherapeutics, Inc. · CIK 1604464 · Engraved from SEC EDGAR
| -$74.57M |
| -$93.35M |
| -$81.31M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.